Browsing "Gastroenterology" by Keyword : Double-Blind Method
Showing results 3 to 13 of 13
Pub Year | | Title | Author(s) |
2010 | | Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. | 신성재 |
2006 | | Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial. | 이은현, 함기백 |
2023 | | Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis | 이광재 |
2023 | | Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study | 이광재 |
2015 | | Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. | 이광재 |
2005 | | Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. | 김진홍, 이광재, 조성원 |
2023 | | Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study | 신성재 |
2004 | | Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. | 이광재 |
2020 | | Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer | 이기명 |
2019 | | Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis | 이광재 |
2017 | | The NO/cGMP pathway in duodenal motor, mechano- and chemosensory responses to acid: A randomized, placebo-controlled study with sildenafil in healthy volunteers | 이광재 |
1